PMID- 17922029
OWN - NLM
STAT- MEDLINE
DCOM- 20080416
LR  - 20220331
IS  - 1476-5594 (Electronic)
IS  - 0950-9232 (Linking)
VI  - 27
IP  - 14
DP  - 2008 Mar 27
TI  - Complex patterns of ETS gene alteration arise during cancer development in the 
      human prostate.
PG  - 1993-2003
AB  - An ERG gene 'break-apart' fluorescence in situ hybridization (FISH) assay has 
      been used to screen whole-mount prostatectomy specimens for rearrangements at the 
      ERG locus. In cancers containing ERG alterations the observed pattern of changes 
      was often complex. Different categories of ERG gene alteration were found either 
      together in a single cancerous region or within separate foci of cancer in the 
      same prostate slice. In some cases the juxtaposition of particular patterns of 
      ERG alterations suggested possible mechanisms of tumour progression. Prostates 
      harbouring ERG alterations commonly also contained cancer that lacked 
      rearrangements of the ERG gene. A single trans-urethral resection of the prostate 
      specimen examined harboured both ERG and ETV1 gene rearrangements demonstrating 
      that the observed complexity may, at least in part, be explained by multiple ETS 
      gene alterations arising independently in a single prostate. In a search for 
      possible precursor lesions clonal ERG rearrangements were found both in high 
      grade prostatic intraepithelial neoplasia (PIN) and in atypical in situ 
      epithelial lesions consistent with the diagnosis of low grade PIN. Our 
      observations support the view that ERG gene alterations represent an initiating 
      event that promotes clonal expansion initially to form regions of epithelial 
      atypia. The complex patterns of ERG alteration found in prostatectomy specimens 
      have important implications for the design of experiments investigating the 
      clinical significance and mechanism of development of individual prostate 
      cancers.
FAU - Clark, J
AU  - Clark J
AD  - Institute of Cancer Research, Male Urological Cancer Research Centre, Sutton, 
      Surrey, UK. jeremy.clark@icr.ac.uk
FAU - Attard, G
AU  - Attard G
FAU - Jhavar, S
AU  - Jhavar S
FAU - Flohr, P
AU  - Flohr P
FAU - Reid, A
AU  - Reid A
FAU - De-Bono, J
AU  - De-Bono J
FAU - Eeles, R
AU  - Eeles R
FAU - Scardino, P
AU  - Scardino P
FAU - Cuzick, J
AU  - Cuzick J
FAU - Fisher, G
AU  - Fisher G
FAU - Parker, M D
AU  - Parker MD
FAU - Foster, C S
AU  - Foster CS
FAU - Berney, D
AU  - Berney D
FAU - Kovacs, G
AU  - Kovacs G
FAU - Cooper, C S
AU  - Cooper CS
LA  - eng
GR  - G0501019/MRC_/Medical Research Council/United Kingdom
GR  - CRUK_/Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20071008
PL  - England
TA  - Oncogene
JT  - Oncogene
JID - 8711562
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (ERG protein, human)
RN  - 0 (Proto-Oncogene Proteins c-ets)
RN  - 0 (Trans-Activators)
RN  - 0 (Transcriptional Regulator ERG)
RN  - EC 3.4.21.- (Serine Endopeptidases)
RN  - EC 3.4.21.- (TMPRSS2 protein, human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Chromosome Aberrations
MH  - DNA-Binding Proteins/*genetics
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Precancerous Conditions/*genetics/pathology
MH  - Prostatic Intraepithelial Neoplasia/*genetics/pathology
MH  - Prostatic Neoplasms/*genetics
MH  - Proto-Oncogene Proteins c-ets/*genetics
MH  - Serine Endopeptidases/genetics
MH  - Tissue Array Analysis
MH  - Trans-Activators/*genetics
MH  - Transcriptional Regulator ERG
EDAT- 2007/10/09 09:00
MHDA- 2008/04/17 09:00
CRDT- 2007/10/09 09:00
PHST- 2007/10/09 09:00 [pubmed]
PHST- 2008/04/17 09:00 [medline]
PHST- 2007/10/09 09:00 [entrez]
AID - 1210843 [pii]
AID - 10.1038/sj.onc.1210843 [doi]
PST - ppublish
SO  - Oncogene. 2008 Mar 27;27(14):1993-2003. doi: 10.1038/sj.onc.1210843. Epub 2007 
      Oct 8.